

the ether extracts were combined and dried with magnesium sulfate, and the ether was distilled. The residue was distilled through a 4-in. Vigreux column to give 4.5 g. (23%) of methyl 6,8-methylenedioxy-2,4-octadienoate, b.p. 108–115° (0.7 mm.), n_D^{25} 1.5180, λ_{\max} 257 m μ , ϵ 23,000.

Anal. Calcd. for C₁₀H₁₄O₄: C, 60.59; H, 7.12. Found: C, 60.14; H, 7.34.

A repetition of this experiment using 55.2 g. (0.40 mole) of methyl heptatrienoate afforded 27.4 g. (34.6%) of methyl 6,8-methylenedioxy-2,4-octadienoate, b.p. 95–124° (0.15 mm.), n_D^{25} 1.5178–1.5200.

Methyl 6,8-methylenedioxyoctanoate. A mixture of 4.31 g. (0.0218 mole) of methyl 6,8-methylenedioxy-2,4-octadienoate, 0.5 g. of 10% palladium-on-carbon, and 100 ml. of hexane was placed in a pressure bottle and hydrogenated in a Parr shaker until hydrogenation was complete. The uptake was 112% of the theoretical amount. The solution was filtered to remove the catalyst, and the solvent was distilled. The residue was fractionated in a 4-in. Vigreux column. There was obtained 3.81 g. (87%) of methyl 6,8-methylenedioxyoctanoate, b.p. 78° (0.1 mm.), n_D^{25} 1.4508–1.4518. The *n-m-r* spectrum was consistent with the structure assigned and was confirmed by comparison with *m*-dioxane and methyl valerate references.

Anal. Calcd. for C₁₀H₁₈O₄: C, 59.41; H, 8.91. Found: C, 59.24; H, 9.00.

The constants listed for this compound³ are b.p., 112° (0.01 mm.) and n_D^{25} 1.4519.

Methyl 6,8-Methylenedioxyoctanoate (direct procedure). A mixture of 19.5 g. (0.65 mole) of paraformaldehyde, 150 ml. of dioxane, and 25 g. of concentrated sulfuric acid was cooled to 0°, and 44.0 g. (0.318 mole) of methyl 2,4,6-heptatrienoate was added. The mixture was stirred at room temperature for 42 hr. and diluted with 300 ml. of ice water. The organic layer was separated, and the water layer was extracted with three 150-ml. portions of ether. The organic layers were combined and dried with magnesium sulfate. The ether was distilled, and the residue was diluted to a volume of 250 ml. with 50% methanol-cyclohexane and hydrogenated using 110 g. of 10% palladium-on-carbon catalyst. Distillation of the product afforded 30.7 g. (48%) of methyl 6,8-methylenedioxyoctanoate, b.p. 94.5° (0.47 mm.) to 102° (0.27 mm.), n_D^{25} 1.4489–1.4498.

Acknowledgment. We are indebted to Dr. G. H. Kalb of this department for the methyl heptatrienoate.

CONTRIBUTION No. 529
CENTRAL RESEARCH DEPARTMENT
EXPERIMENTAL STATION
E. I. DU PONT DE NEMOURS & CO.
WILMINGTON, DEL.

New Route to Carbon-14 Labeled *N*-(1-Hydroxy-2-fluorenyl)acetamide¹

M. A. MORGAN AND H. R. GUTMANN

Received February 20, 1959

The binding of chemical carcinogens or metabolites thereof to cellular proteins is thought to be causally related to the induction of neoplasms.²

(1) Supported by grants from the Graduate School, University of Minnesota, and the National Cancer Institute, U. S. Public Health Service (C-2571).

(2) E. C. Miller and T. A. Miller, *J. Natl. Cancer Inst.*, **15**, 1571 (1955).

In the case of the carcinogen *N*-2-fluorenylacetamide it has been shown that hydroxylation was required for binding of the compound.³ Based on this observation the theory has been advanced that the hydroxylated metabolites are further oxidized to quinone imides or imines and that these reactive metabolites combine with proteins.⁴ Recently, evidence has been provided that 2-amino-1-fluoreneol was oxidized, either by mitochondria and cytochrome c or by cytochrome oxidase and cytochrome c, to the *o*-quinone imine, 1,2-fluoreno-quinone-2-imine. In the presence of crystalline bovine serum albumin this oxidation product added rapidly to the protein.⁵

We desired to determine the mechanism of the oxidation of 2-amino-1-fluoreneol as well as the site and extent of binding of the oxidation product in the intact cell under physiological conditions. For this purpose, we required 2-amino-1-fluoreneol and *N*-(1-hydroxy-2-fluorenyl)acetamide labeled with carbon-14 in the fluorene nucleus. The fluorene system has been shown to be resistant to metabolic attack.⁶

The available chemical synthesis of these compounds^{7,8} from fluoranthene does not permit the incorporation of carbon-14 into the molecule. Carbon-14 labeled *N*-(1-hydroxy-2-fluorenyl)acetamide has been made biosynthetically by feeding *N*-(2-fluorenyl-9-C¹⁴)acetamide to rats and isolating *N*-(1-hydroxy-2-fluorenyl-9-C¹⁴)acetamide from the urine, the label here being situated in the stable 9 position.⁹ The drawback to this method is that it requires the chromatographic separation of the desired *N*-(1-hydroxy-2-fluorenyl-9-C¹⁴)acetamide from other labeled hydroxylated metabolites and the careful purification of the isolated material by carrier methods. *N*-(1-hydroxy-2-fluorenyl)acetamide is only a minor urinary metabolite¹⁰ and the method of isolation necessitates further dilution of the label which places limitations on the specific radioactivity of the final product. For these reasons it appeared desirable to work out an alternative route for the chemical synthesis of carbon-14 labeled *N*-(1-hydroxy-2-fluorenyl)acetamide.

A new approach became possible with the development of a synthesis of 1,2,3,4-tetrahydro-

(3) T. H. Peters and H. R. Gutmann, *Arch. Biochem. Biophys.*, **62**, 234 (1956).

(4) H. R. Gutmann, T. H. Peters, and T. G. Burtle, *J. Biol. Chem.*, **222**, 373 (1956).

(5) H. T. Nagasawa, M. A. Morgan, and H. R. Gutmann, *Biochim. Biophys. Acta.*, **28**, 665 (1958).

(6) H. P. Morris, T. H. Weisburger, E. K. Weisburger, *Cancer Research*, **10**, 620 (1950).

(7) B. Bergmann and M. Orchin, *J. Am. Chem. Soc.*, **71**, 111 (1949).

(8) E. K. Weisburger and T. H. Weisburger, *J. Org. Chem.*, **18**, 864 (1953).

(9) T. H. Weisburger, E. K. Weisburger, P. H. Grantham, and H. P. Morris, *J. Natl. Cancer Inst.*, **22**, 825 (1959).

(10) T. H. Weisburger, E. K. Weisburger, and H. P. Morris, *J. Natl. Cancer Inst.*, **17**, 345 (1956).